19 November 2025 - Roche announced today that the European Commission has granted conditional marketing authorisation of Lunsumio (mosunetuzumab) subcutaneous for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. 

Approval is based on results from the Phase I/II GO29781 study, which showed that Lunsumio subcutaneous had pharmacokinetic non-inferiority compared with intravenous administration, with no unexpected safety signals.

Read Roche press release